Category Specific RSS

Categories: News

Top cosmetic dermatologist endorses Zelira’s cannabis-based acne treatment

In 1964 Israeli chemist Raphael Mcechoulam boarded a bus to the Weitzman Institute in Rehovot with 5 kilos of hashish he received from the Israeli police. He used the material to isolate and identify THC, the psychoactive compound in cannabis. The discovery saw him crowned as “the father of cannabis research”. 

Cannabinoid medicine specialist company Zelira Therapeutics (ASX: ZLD) is paying homage to the scientist by naming their new line of skincare products RAF FIVE. 

The Company has just launched the product line in the US through its dermatology subsidiary Ilera Derm. 

The line uses pharmaceutical-grade CBD in five products including a cleanser, acne spot treatment, moisturiser and SPF and acne treatments. The line will be Zelira’s first foray into the acne medication market worth over USD $11 billion worldwide. 

Alongside acne fighting and skin loving ingredients the products also contain Zylorma, a patent-pending acne treatment developed by Zelira in partnership with cosmetic dermatologist Dr. Karyn Grossman. Zylorma contains a mix of CBD, salicylic acid and other compounds to clear bacteria and unclog pores. 

Following a month of use, 45 people reported significant improvements in their skin including the improvement of blemishes, smoother, more even-toned skin and reduced incidence of blemishes. Results were noticeable after just 7 days’ use. 

CEO and Managing Director of Zelira, Dr. Oludare Odumosu said: “I am excited to announce the launch of Zelira’s Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products. Dr. Grossman’s reputation and experience in the cosmetic dermatology industry, combined with Zelira’s peerless position in a cannabinoid space, is the perfect combination. We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the USD$11 billion acne treatment market where there is a high level of dissatisfaction with the existing products and unmet needs. Zelira is staking a claim in the cannabinoid- based, over- the counter skin care product market with our differentiated dermatology. 

Ilera Derm is working to develop more topical products which are anticipated to be launched next year. 

Samantha Freidin

Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Recent Posts

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

6 days ago

Stakk Secures T-Mobile Contract to Power Super App Expansion

Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…

2 weeks ago

Medibank Backs Emyria with Landmark Depression Care Deal

Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…

3 weeks ago

NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI

NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…

3 weeks ago

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…

1 month ago

Harris Technology eyes profitability as refurbished tech sales surge

In an era of rising living costs and shifting consumer priorities, one Australian company is…

2 months ago